Relief Therapeutics

About:

Relief Therapeutics is a clinical stage biotechnology company.

Website: http://www.relieftherapeutics.com

Twitter/X: ReliefTx

Top Investors: The Global Emerging Markets Group, SWK Funding

Description:

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.